Topic: drug manufacturing
Novartis CEO Vas Narasimhan seeks to cut the company's workforce from 124,000 to under 100,000 by 2022.
Analysts are handicapping Teva's chance of getting its migraine drug candidate approved next week given issues at the plant that will produce it.
Teva is cutting its debt load, but a successful turnaround rests on its new products and late-stage pipeline, analysts say.
In probably a new drug scandal from China, self-proclaimed employees alleged that a Fosun unit faked production and testing records.
Novartis will initially add 260 workers at a new plant in Switzerland to make Kymria and add up to 450 more over time.
Shire could fill Takeda's gap of late-stage assets; GSK lays off 1,000 as a Bangladesh plant nears closure; Laekna gets two Novartis cancer drugs.
Sanofi will close a plant in France with 50 employees and has pledged to address pollution issues there.